{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T06:34:20Z","timestamp":1774852460542,"version":"3.50.1"},"reference-count":22,"publisher":"Termedia Sp. z.o.o.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"published-print":{"date-parts":[[2020,2,28]]},"abstract":"Objectives<\/jats:title>The introduction of vaccinations against viral hepatitis B in the years 1994\u20131996 in Poland significantly improved the epidemiological situation of hepatitis B virus (HBV) infections in our country. According to the report of the National Institute of Public Health \u2013 National Institute of Hygiene in 2018, 40 cases of acute hepatitis B were noted while still in the 1980s between 10 and 20 thousand new cases were reported annually. The aim of the study was to determine whether in children treated with biological drugs (adalimumab, etanercept, infliximab) due to juvenile idiopathic arthritis (JIA), vaccinated against hepatitis B in infancy, a\u00a0protective concentration of anti-HBs antibodies persists. In patients, the value \u2265 10 mIU\/ml is regarded as a\u00a0protective concentration of antibodies, determined at least four weeks after administration of the last vaccine dose. Among healthy individuals, presence of anti-HBs antibodies in any concentration means seroprotection. No booster vaccinations are recommended in basically vaccinated healthy individuals.<\/jats:p><\/jats:sec>Material and methods<\/jats:title>The concentrations of anti-HBs antibodies were determined in 56 children with JIA (38 girls \u2013 67.9% and 18 boys \u2013 32.1%) aged from 2 years and 4 months to 17.5 years, treated for at least three months with biological drugs. The diagnosis of JIA was made based on the International League of Associations for Rheumatology (ILAR) criteria. All studied patients were at the stable stage of the disease and received a full course of hepatitis B vaccination during infancy (in accordance with 0,1,6 months injection scheme).<\/jats:p><\/jats:sec>Results<\/jats:title>In the studied children a\u00a0protective anti-HBs antibody concentration was found in 34 cases (60.7%), and 22 children (39.3%) had anti-HBs antibody concentration < 10 mIU\/ml (in these children no seroprotection was found).<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The post-vaccination antibody concentration should be determined in children with JIA, treated with biological drugs and, in case of absence of a\u00a0protective concentration, revaccination should be started.<\/jats:p><\/jats:sec>","DOI":"10.5114\/reum.2020.93508","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T21:47:56Z","timestamp":1587419276000},"page":"15-20","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of anti-HBs antibody concentration in children with juvenile idiopathic arthritis treated with biological drugs, vaccinated against viral type B hepatitis in infancy"],"prefix":"10.5114","volume":"58","author":[{"given":"Izabela","family":"Szczygielska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Hernik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Gazda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Ko\u0142odziejczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Gietka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"key":"ref-778073","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01522.x"},{"key":"ref-778074","unstructured":"Kuchar E, Mrukowicz J, Stryczy\u0144ska-Kozubal J, et al. Szczepienia przeciwko wirusowemu zapaleniu w\u0105troby typu B. Szczepienia 2017; 4: 88-91."},{"key":"ref-778075","unstructured":"World Health Organization Newletter. Hepatitis B Key facts.Lipiec, 2015. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/ (access: 19.11.2019)."},{"key":"ref-778076","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.344961"},{"key":"ref-778077","unstructured":"Magdzik W, Czarkowski M. Sytuacja epidemiologiczna wirusowego zapalenia w\u0105troby typu B w Polsce w latach 1979\u20132004. [Epidemiological situation of hepatitis B in Poland in the years 1979\u20132004]. Prz Epidemiol 2006; 60: 471-480."},{"key":"ref-778078","unstructured":"Woynarowski M. Polski dzieci\u0119cy program interferonowy leczenia przewlek\u0142ego zapalenia w\u0105troby typu B. Koncepcja, realizacja i efekty. Rozprawa habilitacyjna, Warszawa 2005."},{"key":"ref-778079","unstructured":"Informacje o zachorowaniach na choroby zaka\u017ane i zatruciach w Polsce w 2018 roku. NIPZ-PZH Warszawa, 2019. http:\/\/wwwold.pzh.gov.pl\/oldpage\/epimeld\/2018\/INF_18_12B.pdf (access: 19.11.2019)."},{"key":"ref-778080","unstructured":"Pokorska-Lis M, Marczy\u0144ska M. Czy nastolatki szczepione w wieku niemowl\u0119cym maj\u0105 odporno\u015b\u0107 przeciwko WZW typu B? Prz Lek 2010; 67: 13-17."},{"key":"ref-778081","unstructured":"Kuchar E, Za\u0142\u0119ski A, Koz\u0142owska-Ja\u0142owska A. Profilaktyka poekspozycyjna chor\u00f3b zaka\u017anych. Szczepienia 2018; 2: 76-81."},{"key":"ref-778082","unstructured":"Petty RE, Southwood TR, Manners P, et al. International League of Association for Rheumatology Classification of Juvenile Idiopathic Arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-392."},{"key":"ref-778083","unstructured":"St\u0119pie\u0144 M. Ro\u015bnie liczba przewlek\u0142ych przypadk\u00f3w WZW B w krajach UE\/EEA. https:\/\/szczepienia.pzh.gov.pl\/rosnie-liczba-zglaszanych-przewleklych-przypadkow-wzwb-w-rajach-eu-eea\/ (access: 19.11.2019)."},{"key":"ref-778084","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2015.51503"},{"key":"ref-778085","unstructured":"Maritsi D, Vartzelis G, Soldatou A, et al. Markedly decreased antibody titers against hepatitis B in previously immunised children presenting with juvenile idiopathic arthritis. Clin Exp Rheumatol 2013; 31: 969-973."},{"key":"ref-778086","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215882"},{"key":"ref-778087","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150193"},{"key":"ref-778107","doi-asserted-by":"crossref","unstructured":"Kasap\u00e7opur \u00d6, \u00c7ullu F, Kamburo\u00f0lu-Goksel A, et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1128-1130.","DOI":"10.1136\/ard.2003.013201"},{"key":"ref-778108","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1085608"},{"key":"ref-778113","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.086"},{"key":"ref-778114","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017"},{"key":"ref-778115","doi-asserted-by":"crossref","unstructured":"Silva CA, Terreri MT, Aikawa NE, et al. Vaccination practice in children with rheumatic disease. Rev Bras Reumatol 2010; 50: 351-361.","DOI":"10.1590\/S0482-50042010000300008"},{"key":"ref-778116","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1574151"},{"key":"ref-778117","unstructured":"Rywczak I, \u015aciubisz M. Program szczepie\u0144 ochronnych w Polsce na 2019 rok. Szczepienia 2019; 1: 37-49."}],"container-title":["Rheumatology"],"original-title":["Ocena st\u0119\u017cenia przeciwcia\u0142 anty- HBs u dzieci chorych na m\u0142odzie\u0144cze idiopatyczne zapalenie staw\u00f3w, leczonych lekami biologicznymi, szczepionych przeciwko wirusowemu zapaleniu w\u0105troby typu B w okresie niemowl\u0119cym."],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-118327-85877","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-118327-85877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T08:03:23Z","timestamp":1674806603000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Assessment-of-anti-HBs-antibody-concentration-in-children-with-juvenile-idiopathic,118327,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["118327"],"URL":"https:\/\/doi.org\/10.5114\/reum.2020.93508","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,28]]}}}